STEVANATO GROUP SPA O.N. (87N) - Cash Flow Conversion Efficiency
Based on the latest financial reports, STEVANATO GROUP SPA O.N. (87N) has a cash flow conversion efficiency ratio of 0.049x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€75.49 Million ≈ $88.25 Million USD) by net assets (€1.53 Billion ≈ $1.79 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of STEVANATO GROUP SPA O.N. to measure how many days the company can operate on defensive assets alone.
STEVANATO GROUP SPA O.N. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how STEVANATO GROUP SPA O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
STEVANATO GROUP SPA O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of STEVANATO GROUP SPA O.N. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xinjiang Qingsong Building Materials and Chemicals Group Co Ltd
SHG:600425
|
0.028x |
|
Supriya Lifescience Limited
NSE:SUPRIYA
|
0.051x |
|
S&S TECH Corporation
KQ:101490
|
0.039x |
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
-0.031x |
|
Glencore PLC
LSE:GLEN
|
0.033x |
|
Shanghai Research Institute of Building Sciences Group Co. Ltd A
SHG:603153
|
N/A |
|
BOROSIL RENEWABLES LIMITED
NSE:BORORENEW
|
0.152x |
|
E2E Networks Limited
NSE:E2E
|
0.020x |
Annual Cash Flow Conversion Efficiency for STEVANATO GROUP SPA O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of STEVANATO GROUP SPA O.N. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of STEVANATO GROUP SPA O.N..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.49 Billion ≈ $1.74 Billion |
€286.08 Million ≈ $334.45 Million |
0.192x | +73.50% |
| 2024-12-31 | €1.40 Billion ≈ $1.64 Billion |
€155.78 Million ≈ $182.12 Million |
0.111x | +19.41% |
| 2023-12-31 | €1.13 Billion ≈ $1.32 Billion |
€105.21 Million ≈ $123.00 Million |
0.093x | -10.46% |
| 2022-12-31 | €995.91 Million ≈ $1.16 Billion |
€103.31 Million ≈ $120.78 Million |
0.104x | -34.52% |
| 2021-12-31 | €841.66 Million ≈ $983.99 Million |
€133.34 Million ≈ $155.88 Million |
0.158x | -- |
About STEVANATO GROUP SPA O.N.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprisi… Read more